Trial Profile
A Phase I, open label study of extended dosing with Patrin in combination with temozolomide in the treatment of patients with advanced melanoma. Part 1- to establish a dose for Part 2. Part 2 to test efficacy and safety of the dose established in Part 1.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Lomeguatrib (Primary) ; Temozolomide
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PAT-105
- Sponsors KuDOS Pharmaceuticals
- 30 Aug 2011 New trial record